Skip to content

Study · Animal study (in vivo) · mouse · 2003

4 results

Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy.

Katsuno M, Adachi H, Doyu M, Minamiyama M, Sang C, Kobayashi Y, Inukai A, Sobue G

Nature medicine18 May 2003Cited by 205 (Europe PMC)

PMID12754502 (opens in a new tab)DOI10.1038/nm878 (opens in a new tab)PepBankPUB-12754502
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In male transgenic SBMA mice, leuprorelin rescued motor dysfunction.

    In plain wordsIn mice with SBMA, leuprorelin reduced motor dysfunction.

    Peptide
    Leuprolide
    Outcome
    DecreaseMotor dysfunction
    Study

    mousen: not reported in source

    Male transgenic SBMA mice
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Leuprorelin, a lutenizing hormone-releasing hormone (LHRH) agonist that reduces testosterone release from the testis, rescued motor dysfunction and nuclear accumulation of mutant androgen receptors in male transgenic mice.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In male transgenic SBMA mice, leuprorelin rescued nuclear accumulation of mutant androgen receptors.

    In plain wordsIn mice with SBMA, leuprorelin reduced mutant androgen receptor accumulation in nuclei.

    Peptide
    Leuprolide
    Outcome
    DecreaseNuclear accumulation of mutant androgen receptors
    Study

    mousen: not reported in source

    Male transgenic SBMA mice
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Leuprorelin, a lutenizing hormone-releasing hormone (LHRH) agonist that reduces testosterone release from the testis, rescued motor dysfunction and nuclear accumulation of mutant androgen receptors in male transgenic mice.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In transgenic mice, leuprorelin reversed behavioral phenotypes caused by transient serum testosterone increases.

    In plain wordsIn mice, leuprorelin reversed behavioral changes caused by temporary testosterone increases.

    Peptide
    Leuprolide
    Outcome
    DecreaseBehavioral phenotype
    Study

    mousen: not reported in source

    Male transgenic SBMA mice
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Moreover, leuprorelin treatment reversed the behavioral and histopathological phenotypes that were once caused by transient increases in serum testosterone.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In transgenic mice, leuprorelin reversed histopathological phenotypes caused by transient serum testosterone increases.

    In plain wordsIn mice, leuprorelin reversed tissue changes caused by temporary testosterone increases.

    Peptide
    Leuprolide
    Outcome
    DecreaseHistopathological phenotype
    Study

    mousen: not reported in source

    Male transgenic SBMA mice
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Moreover, leuprorelin treatment reversed the behavioral and histopathological phenotypes that were once caused by transient increases in serum testosterone.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.